GI ASCO 2023 Highlights with Dr. Mark Lewis

Discussing GI ASCO 2023 Highlights - practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.

• SPOTLIGHT - Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
• NAPOLI3 - Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
• Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
• MOUNTAINEER - FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
• SUNLIGHT - Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com